BioXcel Therapeutics, Inc. (BTAI)
| Market Cap | 858.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -99.83M |
| Shares Out | 24.96M |
| EPS (ttm) | -4.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200,216 |
| Open | 31.45 |
| Previous Close | 32.03 |
| Day's Range | 30.28 - 31.67 |
| 52-Week Range | 23.07 - 67.74 |
| Beta | 1.06 |
| Analysts | Strong Buy |
| Price Target | 92.55 (+201.7%) |
| Est. Earnings Date | Nov 11, 2021 |
About BTAI
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. h...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for BTAI stock is "Strong Buy." The 12-month stock price forecast is 92.55, which is an increase of 201.66% from the latest price.
News
BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery and Development and Advances ...
Management to showcase AI platform to develop potential treatments for neuropsychiatric disorders
BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressi...
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma
BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ...
NEW HAVEN, Conn., Sept. 12, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...
BioXcel Therapeutics to Host Virtual R&D Day on September 23, 2021
Live webcast, Revolutionizing Drug Discovery and Development Through AI, to be held from 12:00 PM ET – 2:00 PM ET
BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021
This Under-the-Radar Dementia Treatment Could Reward Investors
Want to dabble in the market for Alzheimer's therapies but avoid Biogen? Look no further.
BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021
NEW HAVEN, Conn., July 28, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence a...
BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive Offic...
Here's Why BioXcel Therapeutics Stock Got Hammered This Week
Investors weren't happy about a secondary share offering.
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
NEW HAVEN, Conn., June 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an u...
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to ...
BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021
Live webcast to be held on June 25th from 12:00 PM ET – 1:30 PM ET Live webcast to be held on June 25th from 12:00 PM ET – 1:30 PM ET
BioXcel's Formulated Dexmedetomidine US Application For Agitation Under FDA Review
The FDA has accepted for review, BioXcel Therapeutics Inc's (NASDAQ: BTAI) marketing application for BXCL501, an orally dissolving thin film formulation of dexmedetomidine. The application covers the ac...
BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Asso...
FDA sets PDUFA action date for January 5, 2022
BioXcel Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Granted FDA Breakthrough Therapy designation for BXCL501 for the acute treatment of agitation associated with dementia; registrational program expected to begin in 2H 2021
BioXcel Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ap...
BioXcel Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast
NEW HAVEN, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ap...
BioXcel Therapeutics Announces Presentations on SERENITY I & II at the 2021 American Psychiatric Association Annual M...
NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fi...
New York, New York--(Newsfile Corp. - April 16, 2021) - Levi & Korsinsky announces it has commenced an investigation of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) concerning possible breaches of fiduciar...
Why BioXcel Therapeutics Stock Is Plunging Today
Investors were not impressed with the biotech's latest clinical update.
BioXcel Stock Is Trading Lower After BXCL501 Data In Opioid Withdrawal Study
BioXcel Therapeutics Inc (NASDAQ: BTAI) has announced topline results from its Phase 1b/2 proof-of-concept RELEASE study evaluating BXCL501 for the treatment of opioid withdrawal symptoms. BXCL501 is th...
BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal Symptoms
Primary safety endpoint achieved in first study of BXCL501 dosed twice-daily over seven days
FDA Gives Accelerated Review Tag To BioXcel's BXCL501 In Dementia-Related Agitation
The FDA has designated Breakthrough Therapy status to BioXcel Therapeutics Inc's (NASDAQ: BTAI) BXCL501, to treat agitation associated with dementia. The designation intends to expedite the development ...
BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation A...
Designation offers the potential for expedited development and review, highlighting the urgent need for new treatment options for dementia related agitation Designation offers the potential for expedite...
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation